Background:
Human amniotic membrane grafting could be potentially useful in ocular surface
complications due to tissue similarity and the presence of factors that reduce inflammation, vascularization,
and scarring. However, considerations like donor-derived infectious risk and the requirement
of an invasive surgery limit the clinical application of such treatments. Moreover, the quick depletion
of bioactive factors after grafting reduces the efficacy of treatments. Therefore, in the current
study, the possibility of nano delivery of the bioactive factors extracted from the human amniotic
membrane to the ocular surface was investigated.
Materials and methods:
Nanoparticles were prepared using polyelectrolyte complexation from chitosan
and dextran sulfate. The effect of polymer ratio, pH, and the amount of extract on particle size
and encapsulation efficacy were studied using Box-Behnken response surface methodology.
Results:
The optimum condition was obtained as follows: 4.9:1 ratio of dextran sulfate to chitosan, 600
µL amniotic membrane extract, and pH of 6. The prepared nanoparticles had an average size of 213
nm with 77% encapsulation efficacy. In the release test, after 10 days, approximately 50% of entrapped
bioactive proteins were released from the nanocarriers in a controlled manner. Biological activity assessment
on endothelial cells revealed amniotic membrane extract loaded nanoparticles had a longer
and significant increase in anti-angiogenic effect when compared to the control.
Conclusion:
Our data elucidate the ability of nanotechnology in ocular targeted nano delivery of bioactive
compounds.
Dehydrated human amniotic membrane regulates tenocyte expression and angiogenesis
in vitro
: Implications for a therapeutic treatment of tendinopathy
